- If you have any queries please email email@example.com
|28 July 2020
|Suspended. The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Abicipar pegol for treating wet age-related macular degeneration. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
|09 April 2020
|Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
|29 May 2019 - 26 June 2019
|Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
For further information on our processes and methods, please see our CHTE processes and methods manual